Condition (MeSH)
Optic Nerve Injuries
ClinicalTrials.gov lists 18 trials for Optic Nerve Injuries or a narrower condition beneath it. MD Stem Cells has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
16 of the 18 trials are tagged with Optic Nerve Injuries itself; the rest are tagged with a narrower condition beneath it.
When did Optic Nerve Injuries trials start? (13)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Not applicable
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2024 | 1 |
| 2022 | 2 |
| 2020 | 2 |
| 2019 | 2 |
| 2018 | 1 |
| 2017 | 2 |
| 2016 | 1 |
| 2015 | 1 |
| 2014 | 1 |
Showing 10 of 13 earlier years.
No forecast is made for this condition: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Optic Nerve Injuries trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 4 |
| Phase 1/2 | 1 |
| Phase 2 | 2 |
| Phase 2/3 | 1 |
| Phase 3 | 2 |
| Not applicable | 8 |
How many Optic Nerve Injuries trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 3 |
| Completed | 7 |
| Unknown status | 7 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Optic Nerve Injuries trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| MD Stem Cells | 2 |
| Qingdao WanMing BioCell Pharmaceutics Co.,Ltd. | 1 |
| Regenera Pharma Ltd | 1 |
Which drugs are being tested for Optic Nerve Injuries? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| METHYLPREDNISOLONE | 2 |
| PEGFILGRASTIM | 1 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Recombinant Human Erythropoietin | 2 |
| AlloRx | 1 |
| RPh201 | 1 |
| Mitomycin C 0.02% | 1 |
| Recombinant human nerve growth factor injection,multiple dose | 1 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Optic Nerve Injuries trials report? (5)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Brucellosis | 1 | 1 |
| Dizziness | 1 | 1 |
| Ischemic optic neuropathy - AION right eye | 1 | 1 |
| Vertigo | 1 | 1 |
| Visual acuity decreased | 1 | 1 |
Which publications cover Optic Nerve Injuries? (23)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Traumatic Optic Neuropathy Treatment Trial 2 (TONTT-2): evaluating the efficacy of different doses of erythropoietin - a multicentre, randomised, double-blind clinical trial. | The British journal of ophthalmology | 2025 | Yes |
| Treatment of traumatic optic neuropathy using human placenta-derived mesenchymal stem cells in Asian patients. | Regenerative medicine | 2020 | Yes |
| UMSC-derived exosomes promote retinal ganglion cells survival in a rat model of optic nerve crush. | Journal of chemical neuroanatomy | 2019 | Yes |
| Traumatic optic neuropathy treatment trial (TONTT): open label, phase 3, multicenter, semi-experimental trial. | Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie | 2018 | Yes |
| The neuroprotective effect of latanoprost acts via klotho-mediated suppression of calpain activation after optic nerve transection. | Journal of neurochemistry | 2017 | Yes |
Showing 5 of 23 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.